Roche delays acquiring Spark as regulatory review process continues
Category: #health  By Mateen Dalal  Date: 2019-05-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Roche delays acquiring Spark as regulatory review process continues

Roche, the leading Swiss pharma has pushed back its scheduled acquisition of the gene therapy specialist, Spark Therapeutics for third time in a row, as it waits for the U.S. government to complete regulatory review of the proposed $4.3 billion takeover.

As per credible source, Spark and Roche plan to refile their Premerger Notification and Report Forms in order to provide additional time to the government for the review. The acquisition is regulated by the antitrust Hart Scott Rodino Act, 1976.

In a joint statement, the companies have said they are actively working with the government to expediate the process. Spark and Roche did not disclose the specifics as to why the government needs additional time to review the deal. Roche did perceive that the acquisition could have been completed earlier, if the government granted early termination of waiting period, cites source.

Reportedly, Roche has said that the FTC (Federal Trade Commission) requires more time to complete the review.

For the record, Spark is the pioneering biotech company to commercialize a gene therapy for a genetic disease in the U.S. In December 2017, the Unites States Food and Drug Administration approved Spark’s Luxturna, a gene therapy for a rare genetic type of blindness. FDA Commissioner Scott Gottlieb said at the time of approval, that gene therapy will become a mainstream form of treating and maybe even curing various diseases.

Since the approval of Luxturna, Spark has been advancing a remarkable gene therapy treatment for Hemophilia A. Last August, the company released data that indicated a 97% response rate for reduced bleeding events in patients. The updated data was provided at American Society of Hematology meeting and it continues to exhibit strong response from the patients and has a strong safety profile, says the company. This is expected to supplement Roche’s hemophilia treatment, Hemlibra. Last year’s approval for a second indication has made Hemlibra the only available treatment for Hemophilia A.

Source credits: https://in.reuters.com/article/us-spark-m-a-roche/roche-pushes-back-spark-takeover-again-as-regulatory-review-drags-on-idINKCN1SK0GL

https://www.biospace.com/article/the-roche-acquisition-of-spark-hits-a-delay-due-to-regulatory-review-process/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
By Mateen Dalal

The acquisition would help Merck strengthen its presence in the renal cell carcinoma space and support its cancer drug portfolio. U.S. pharmaceutical conglomerate, Merck & Co. Inc. has recently agreed to purchase Dallas based Peloton Therapeutic...

Ikea invests in India’s one-stop interior design platform Livspace
Ikea invests in India’s one-stop interior design platform Livspace
By Mateen Dalal

The interior design platform had raised over $70 million last year with investment from TPG Growth & Goldman Sachs. The investment is Ikea’s first such deal in India, however it isn’t the company’s dalliance in India’s ...

BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
By Mateen Dalal

Sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic for the acute treatment of agitation Reports confirm that BioXcel Therapeutics (BTI) has recently presented data from its Phase 1 pharmacokinetic (bioavailabil...